Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic Chemotherapy

1 Jul 2006

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to Hepatitis C virus research
Share to Liver Diseases and Immunity

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 16831590
DOI: 10.1053/j.gastro.2006.04.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic ChemotherapyPMID 16831590Read ↗

Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.Semantic proximity Read ↗

Fatal reactivation of hepatitis B virus mutant following cytotoxic treatment.Semantic proximity Read ↗

Hepatitis B virus reactivation during cytotoxic chemotherapy‐enhanced viral replication precedes overt hepatitisSemantic proximity Read ↗

HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune TolerantSemantic proximity Read ↗

Persistent risk for hepatocellular carcinoma after more than a decade of successful hepatitis B virus suppression.Semantic proximity Read ↗

Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.Semantic proximity Read ↗

Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important roleSemantic proximity Read ↗

Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.Semantic proximity Read ↗

Characterization of the molecular events of covalently closed circular DNA synthesis in de novo Hepatitis B virus infection of human hepatoma cellsSemantic proximity Read ↗

Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt.Semantic proximity Read ↗

Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy.Semantic proximity Read ↗

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.